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We hypothesize that patients with poor collaterals on baseline CTA will not achieve good clinical outcome with endovascular therapy or intravenous tissue-type plasminogen activator (tPA), patients with moderate collaterals will likely do well with additional endovascular therapy, whereas patients with good collaterals at baseline may do equally well with both therapies. We base our hypothesis on the assumption that patients with good collateral status (moderate ischemia) at baseline may have longer time windows for tissue salvage, obviating the importance of faster recanalization with endovascular treatment. Patients with poor collaterals at baseline may not have any salvageable brain even if early recanalization is achieved, whereas patients with intermediate collaterals may have severe ischemia and are therefore most likely to benefit from early recanalization offered by additional endovascular therapy.
Methods
Data are from the IMS III study. Of 656 patients enrolled in the study, 306 patients had CTA at baseline. Details of the IMS III study protocol have been described previously.
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Imaging Analyses
Baseline and follow-up images were analyzed at the imaging core laboratory using OsiriX version 3.5 (http://www.osirix-viewer.com) to reconstruct 2-dimensional (2D) multiplanar reconstruction images of baseline CTA in axial, coronal, and sagittal planes using 3-mm and 24-mm thick slabs. Collateral status was measured on baseline CTA indirectly by measuring the extent of backfilling pial arteries beyond an intracranial occlusion. 1, 3 The size of these backfilling arteries and the extent to which they fill the ischemic territory were compared with the opposite normal hemisphere. Because assessment of backfilling pial arteries in more distal occlusions is technically difficult, collateral status was only measured in patients with proximal occlusions (ie, trunk of middle cerebral artery [MCA] M1 ± intracranial internal carotid artery occlusion). 3, 4 We chose 3 different scoring systems to assess collateral status on baseline CTA. The regional collateral scoring system (score 1) is derived from a previously published score and distinguishes the extent and prominence of backfilling pial arteries in the anterior cerebral artery (ACA)-MCA and posterior cerebral artery (PCA)-MCA region separately.
14 ACA-MCA and PCA-MCA pial arterial backfilling are each scored from 0 to 5 (0-absent, 1-minimal, 2-significantly decreased prominence and extent of pial arteries with regions of no vessels, 3-moderately decreased prominence and extent, 4-mildly decreased prominence and extent, 5-normal or increased prominence and extent) when compared with the opposite normal hemisphere; the total score combines scores from these 2 regions to give an ordinal score ranging from 0 to 10.
14 Score 2 (Maas et al) 5 is based on a previously published ordinal scoring system that rates pial arterial backfilling primarily in the sylvian sulcus (0-absent, 1-poor, 2-less, 3-equal, 4-greater and 5-exuberant) when compared with the opposite hemisphere; Score 3 (Tan et al) 7 is a previously published score that assesses pial arterial backfilling in the whole MCA ischemic territory (0, minimal; 1, <50%; 2, >50%; 3-pial arteries filling 100% of ischemic territory). These 3 scoring systems represent the entire spectrum of scoring systems for collaterals on CTA Head examinations.
Because all CTAs in IMS III were single-phase examinations and collateral status can be significantly underestimated if scan acquisition is triggered early, data on CTA image acquisition timing were collected (Hounsfield Units [HU] of the contralateral internal carotid 14, 15 We defined a scan as early arterial-weighted if the mean HU in the arterial side was <150 HU and greater than the mean venous HU. 8 In addition, relative prominence of pial arteries versus veins was measured on the ischemic side and the contralateral normal side, and a scan was considered to be early arterial-weighted if pial arteries were more prominent than the veins on the contralateral side. All scans were scored for image quality. Scans were considered poor quality if collateral assessment was not possible because of incomplete brain coverage or severe motion. Two readers (B.K.M., V.N.) read all scans by consensus; the readers were blinded to all clinical and follow-up data at the time of reading the scans.
Statistical Analyses
Data were summarized using standard descriptive statistics. Collateral status on CTA using the 3 scores described above was trichotomized into 3 groups. Using categories good, intermediate, and poor, the 3 scores were as follows; Score 1(good 8-10, intermediate 6-7, poor 0-5), Score 2 (good 3-5, intermediate 2, poor 0-1), and Score 3 (good 3, intermediate 2, poor 0-1; Table 1 ). Different score cut points (Score 1: 0-2/3-7/8-10 and Score 2: 0-1/2-3/4-5) and alternate collateral categorization (good/intermediate versus poor) were used for sensitivity analyses. For the primary outcome (modified Rankin Scale [mRS] 0-2 at 90 days), we used a generalized linear model with log link and allowed for a possible interaction between treatment and collateral status. Because the available sample size limited statistical power to detect an interaction, we additionally examined models within each collateral group to assess whether treatment type was associated with good clinical outcome. If we were unable to demonstrate heterogeneity of treatment effect by collateral status, we presented models with treatment type and collateral status, adjusted for age (continuous), National Institutes of Health Stroke Scale (NIHSS) score (≤19 versus ≥20), and time from stroke symptom onset to intravenous tPA initiation (≤2 hours versus >2 hours). Both collateral status and baseline NIHSS were included in the model only after consideration of the variance inflation factor suggested that collinearity was not a concern. Twenty-four-hour recanalization as measured by CTA was not included in the adjusted model because it is not a baseline variable and may be associated with treatment type. Baseline ASPECTS also was not included in the model given our a priori hypothesis and previous literature, suggesting reduced inter-rater reliability in the early presenters. Similar model building exercises were repeated with 90-day mRS 0-1 as outcome.
Finally, we assessed 90-day mRS as an ordinal outcome. The generalized Wilcoxon test was used to test for the presence of a shift in 90-day mRS distributions by treatment group (intravenous tPA versus additional endovascular treatment) stratified by collateral status (good, intermediate, or poor). We used an ordinal logistic regression model with mRS as the dependent variable to test for an interaction between treatment type and collateral status. The proportional odds assumption was tested. The final reported models were adjusted for age, baseline NIHSS, and time from stroke symptom onset to intravenous tPA initiation.
Results
Of 656 patients enrolled in the IMS III trial, 306 patients had CTA Head at baseline, of which 204 had intracranial M1 MCA ± intracranial internal carotid artery occlusion. 12 After excluding 15 patients with either incomplete CTA coverage or unavailable scans and 4 patients with poor image quality, 185 patients were included in the final analysis (59 patients in the intravenous tPA only arm [60.5% recanalized at 24 hours, 30.5% achieved 90-day mRS 0-2] and 126 patients in the endovascular therapy arm [87.6% recanalized at 24 hours, 41.3% achieved 90-day mRS 0-2]). Baseline clinical and imaging characteristics, including collateral status, are described in Table 2 ; treatment arms were well matched.
Primary Clinical Outcome (90-Day mRS 0-2)
Ninety-day good clinical outcome (mRS 0-2) within each treatment type (intravenous tPA alone versus endovascular therapy) stratified by collateral score categories (good, intermediate, and poor) across all 3 collateral scores is shown in Table 3 . The point estimate difference between treatment types for good clinical outcome rate (mRS 0-2) seems to differ by collateral status; patients with intermediate collaterals do best with endovascular therapy, those with good collaterals tend to do better, whereas patients with poor collaterals tend to do marginally worse with endovascular therapy (However, all confidence intervals of all point estimates include zero). In multivariable modeling, the 3 collateral scores were each significant predictors of 90-day mRS 0 to 2 within their respective models (P values <0.01 for all scores), whereas the effect of type of treatment (intravenous tPA alone versus 
Secondary Clinical Outcome (90-Day mRS 0-1)
For 90-day mRS 0 to 1, statistically significant difference in rate of good clinical outcome between treatment types, favoring endovascular therapy, is noted in patients with intermediate collateral status on all 3 scores (P<0.05; Table I in the online-only Data Supplement). In multivariable modeling, the 3 collateral scores were each significant predictors within their respective models (P<0.05 for all 3 models), whereas the effect of type of treatment (intravenous tPA alone versus endovascular therapy) was significant using scores 1 and 2 (P<0.05). The interaction term between collateral score and type of treatment was nonsignificant in score 2 and score 3 models (P>0.1). The model for score 1 is not reported because of a complete separation of data points.
Shift Analysis Across the mRS Scale
In univariate analysis, a statistically significant shift in 90-day mRS distribution between intravenous tPA only and endovascular therapy arms was noted only for subjects with intermediate collateral status as defined by score 1 (P=0.01) and score 2 (P=0.01). Shifts in mRS distribution for patients with good or poor collaterals across all 3 scores were not significant (P>0.05; Figure; and Table II 
Sensitivity Analyses
In sensitivity analyses with the primary outcome (mRS 0-2 at 90 days), results remained consistent when using alternate trichotomization cut points for collateral status (Score 1: 0-2/3-7/8-10 and Score 2: 0-1/2-3/4-5 
Discussion
Our results show that collateral status measured on baseline single-phase CTA of the head is a robust independent predictor of clinical outcome in patients enrolled in the IMS III trial. We also are able to show some evidence that additional endovascular treatment in the treatment-time window of IMS III are likely to benefit patients with good and intermediate collateral status, with maximal benefit seen in patients with intermediate collaterals. Our results are consistent across different methods of CTA collateral assessment. 5, 7, 14 Small number of patients limits the power of the current analysis and so effect modification of the relation between treatment type and clinical outcome by collateral status was not observable. Larger data sets may be useful to sort out this question.
Multiple studies have shown that baseline CTA collaterals determine clinical outcome in patients with acute ischemic stroke. [3] [4] [5] [6] Some previous studies also have shown effect modification of the relation between recanalization status and clinical outcome by collateral status. 4, 9, 16 Our study demonstrates the effect of CTA collateral status on clinical outcome within a large randomized controlled trial (IMS III). 11 Similar results have been demonstrated using collaterals on conventional angio in IMS III. 13 Although our results do not convincingly demonstrate effect modification by collateral status, these results could be used to support the use of CTA collateral status as an imaging selection tool to select patients for endovascular therapy in clinical trials and potentially in clinical practice. The testing benefit of additional Endovascular therapy over current Standard of Care in patients with Acute ischemic stroke and Proximal intracranial occlusions (ESCAPE) trial has incorporated baseline CTA collateral status (good and intermediate) as an important selection criteria for trial enrollment. 17 Our results show that the differential effect of additional endovascular therapy versus intravenous tPA alone is likely maximal in patients with intermediate CTA collaterals. These patients are more likely to have severe ischemia and consequently grow their baseline infarct at a faster rate. 9 They are also more likely to have longer intracranial thrombus (because of poorer backfilling pial arteries resulting in stasis distal to original thrombus) that is less likely to recanalize early with intravenous tPA alone. 8 Endovascular therapy offers a higher likelihood of early recanalization in these patients versus intravenous tPA alone, thus preventing significant infarct growth from happening and improving clinical outcome. In comparison, patients with good baseline CTA collaterals may grow infarcts at a slower rate and allow more time for intravenous tPA to reopen the clot before permanent brain injury. These patients therefore may have a higher chance of doing well with intravenous tPA alone; endovascular therapy may only benefit additionally if recanalization is achieved early. Patients with poor baseline CTA collaterals have a high likelihood of having severe ischemia, large baseline infarcts, and large thrombus burden. 9 Endovascular therapy, if successful in achieving reperfusion in such patients, could put them at risk of reperfusion injury and consequent harm. Other studies have also shown marginal harm in such patients using perfusion imaging. [18] [19] [20] Our study has some limitations. CTA was only done in a proportion of patients within the IMS III trial. As such, our study was underpowered to show statistical interaction in multivariable modeling exercises. All CTAs within the IMS III trial are single-phase CTA Head examinations; this technique lacks temporal resolution unlike dynamic or multiphase CTA and therefore runs the risk of mislabeling collateral status. 14, 15, 21 To account for this limitation, we did detailed analysis of bolus timing, conducting sensitivity analysis excluding patients with early arterial-weighted scans and correcting for possible mislabeling of collateral status. These sensitivity analyses were consistent with our overall results.
In conclusion, using data from a large randomized controlled trial (IMS III), we show that baseline CTA collaterals are a robust determinant of clinical outcome. Patients with good/ intermediate collaterals may benefit from additional endovascular therapy, whereas those with poor collaterals may not. 
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